Cryotherapy

New treatment option for prostate cancer shows successful outcomes

Retrieved on: 
Saturday, March 23, 2024
Disease, Radiation, Cryotherapy, Hatred, Collateral damage, MRI, Prostate cancer, Average revenue per user, Urology, Heat, FASR, Risk, Patient, Lung, Neoplasm, Research, Cancer, Calcification, Standard of care, Radiology, Prostate, Society, Urinary incontinence, Kidney, Erectile dysfunction, PCA, PSA, UCLA, Urethra, Medical imaging

FAIRFAX, Va., March 23, 2024 /PRNewswire/ -- A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation is effective in treating prostate cancer, according to new research to be presented at the Society of Interventional Radiology Annual Scientific Meeting in Salt Lake City.

Key Points: 
  • "Prostate cancer is the most common form of cancer in men, affecting one in eight men in their lifetimes.
  • According to Dr. Raman, "This image-guided therapy maximizes our ability to kill cancer cells while minimizing collateral damage to the prostate to achieve the ultimate trifecta in prostate cancer treatment: full local cancer control while maintaining urinary continence and potency.
  • The latter are the complications of most prostate cancer therapies that patients hate and often result from a lack of precision in treatment monitoring."
  • Abstract #135 : Five-year outcomes after MRI-guided transurethral ultrasound ablation (TULSA) of localized prostate cancer.

Nielsen Biosciences Announces Enrollment of First Patient in Phase 3 Trial of CANDIN for the Treatment of Common Warts

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Doctor of Philosophy, MD, FDA, Infection, Cryotherapy, Skin, Common, MBA, Finger, Viral, Safety, Nielsen, Wart, Patient, Clinical trial, HPV, FAAD, Trial of the century, Pharmaceutical industry

Nielsen BioSciences, Inc. (“Nielsen”), a privately-held, San Diego-based biopharmaceutical company, today announced the first patient enrolled in CFW-3A – a Phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of CANDIN® for the treatment of Verruca vulgaris (common warts) in adolescents and adults.

Key Points: 
  • Nielsen BioSciences, Inc. (“Nielsen”), a privately-held, San Diego-based biopharmaceutical company, today announced the first patient enrolled in CFW-3A – a Phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of CANDIN® for the treatment of Verruca vulgaris (common warts) in adolescents and adults.
  • Nielsen is partnering with Maruho Co. Ltd. (“Maruho”) in the clinical development program for CANDIN.
  • “The first patient treated with CANDIN represents a major milestone for the company, and for patients affected by common warts around the world,” said David P. Burney, PhD, MBA, President and Chief Operating Officer at Nielsen BioSciences.
  • Common warts are estimated to affect approximately 10 percent of the global population.1 There are currently no FDA-approved prescription treatments.

Red Sea Global and Four Seasons Announce New Luxury Wellness Resort and Residences at AMAALA Triple Bay

Retrieved on: 
Wednesday, March 6, 2024
Nature, Collection, Light, Regeneration, Discovery Centre, Water garden, Architecture, Kingdom Centre, Tourism, Cryotherapy, Tranquillity, Residence, Water, RSG, Good, Corniche, NEOM, Season, Music, Hotel

RIYADH, Saudi Arabia, March 6, 2024 /PRNewswire/ -- Red Sea Global (RSG), the developer behind the regenerative tourism destinations AMAALA and The Red Sea, and leading luxury hospitality and branded residential company Four Seasons announce the development of a new luxury wellness resort and Private Residences at Triple Bay AMAALA.

Key Points: 
  • With uninterrupted views of the Hijaz Cove, Four Seasons Resort and Residences AMAALA at Triple Bay is designed to allow guests and residents to get back to nature, recharging their mind, body, and soul," says John Pagano, Group CEO of Red Sea Global.
  • "Our new Resort and Residences in AMAALA at Triple Bay will perfectly complement Four Seasons growing collection of properties within the Kingdom's dynamic destinations, and marks our second collaboration with Red Sea Global," says Bart Carnahan , President, Global Business Development, Portfolio Management and Residential, Four Seasons.
  • Four Seasons Resort and Residences AMAALA at Triple Bay will include a luxury spa nestled within its garden of tranquillity and inspiration featuring a sculptured waterfall.
  • For more images of Four Seasons Resort and Residences AMAALA at Triple Bay, please see here .

Degree Wellness Celebrates the Opening of its National Headquarters

Retrieved on: 
Tuesday, March 5, 2024
Partnership, Growth, Cryotherapy, Film industry

JACKSONVILLE, Fla., March 5, 2024 /PRNewswire/ -- Degree Wellness®, the premier self-care experience that empowers people to feel, look, and be their best selves, is proud to announce the opening of its national headquarters in downtown Jacksonville, Florida.

Key Points: 
  • JACKSONVILLE, Fla., March 5, 2024 /PRNewswire/ -- Degree Wellness®, the premier self-care experience that empowers people to feel, look, and be their best selves, is proud to announce the opening of its national headquarters in downtown Jacksonville, Florida.
  • "Opening our national headquarters is a milestone for Degree Wellness," said Amanda Lightcap, the company's President.
  • In conjunction with its new headquarters, Degree Wellness is also opening its newest retail location.
  • To commemorate the opening of its Riverside studio and new headquarters, Degree Wellness will host a grand opening event on Saturday, March 23, offering the community a chance to explore its services and learn more about the brand.

ChemoMouthpiece, LLC. Announces the Awarding of the 510(k) Marketing Clearance by the FDA for their Oncology Supportive Care Device and Recent Closing of their Private Placement Round

Retrieved on: 
Thursday, February 22, 2024
Vasoconstriction, Incidence, Marketing, ONS, Oncology Nursing Society, Multimedia, ASCO, FDA, News, Pain, Hodgkin lymphoma, Cryotherapy, Nausea, Manuscript, Risk, Mouth, Society, Wastewater treatment, Patient, Chemotherapy, Clinical trial, Lymphoma, Mucositis, Dentistry

announces the FDA 510(k) Marketing Clearance for their device, The Chemo Mouthpiece™.

Key Points: 
  • announces the FDA 510(k) Marketing Clearance for their device, The Chemo Mouthpiece™.
  • has just closed on their Private Placement Round of $10 million in upfront capital with a full commitment for the second tranche of additional funds in excess of $10 million.
  • "Chemo Mouthpiece™ is fully stocked, as we will begin shipping across the US within the next quarter now that we have FDA Marketing Clearance.
  • ChemoMouthpiece, LLC is a privately held medical device company that develops and commercializes propriety oral cryotherapy products for cancer patients.

ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe

Retrieved on: 
Wednesday, February 14, 2024
Biotechnology, Health, Surgery, Medical Devices, Temperature, NDRA, Cryotherapy, Integration, European Patent Convention, Medical imaging

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of three new patents, including one in the U.S., one in China and one in Europe.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of three new patents, including one in the U.S., one in China and one in Europe.
  • ENDRA’s intellectual property portfolio now includes 74 issued patents worldwide providing protection for the TAEUS system with its novel thermoacoustic technology.
  • These patents protect novel innovations integral to the TAEUS system, ensuring maximum radiofrequency energy absorption, minimized signal noise and precise temperature monitoring during surgical procedures and thermal ablation.
  • "We remain committed to fortifying our intellectual property to safeguard our technology in key global markets, deploying a robust portfolio that now encompasses 74 granted patents."

Medical Director of Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies’ Medical and Scientific Advisory Board and Incorporates CyPath® Lung into Medical Practice

Retrieved on: 
Tuesday, February 6, 2024
Technology, Biotechnology, Health, Radiology, Pharmaceutical, Surgery, Artificial Intelligence, Oncology, Research, Medical Devices, Genetics, Health Technology, Science, Clinical Trials, Coagulation, Patient, BIAF, Lung cancer, Medicine, Cryotherapy, Physician, Lung, Plasma

Lung Innovations Network, a patient-centered practice that offers comprehensive lung care to over 10,000 patients in central and western Pennsylvania, will incorporate CyPath® Lung into its practice to aid in the detection of early-stage lung cancer.

Key Points: 
  • Lung Innovations Network, a patient-centered practice that offers comprehensive lung care to over 10,000 patients in central and western Pennsylvania, will incorporate CyPath® Lung into its practice to aid in the detection of early-stage lung cancer.
  • “As a clinician, I see hundreds of patients a year who can directly benefit from CyPath® Lung, bioAffinity’s patient-friendly, noninvasive test for lung cancer.
  • As a researcher, I am excited about the Company’s ongoing studies to advance CyPath® Lung, as well as noninvasive tests for other lung diseases,” Dr. Bansal said.
  • Bansal is a highly regarded clinician and researcher who will be a strong addition to our stellar Medical and Scientific Advisory Board.

Enhancing Chiropractic Practices: A Comprehensive Guide to Essential Equipment

Retrieved on: 
Thursday, January 11, 2024
Table, Patient, Tendon, Spinal cord compression, Health, Multimedia, TENS, Ligament, Pain, Inflammation, Cryotherapy

DALLAS, Jan. 11, 2024 /PRNewswire-PRWeb/ -- In the realm of chiropractic care, success is not solely dependent on effective treatment and superior patient service; it also hinges on the strategic investment in cutting-edge equipment. As practitioners strive to elevate their offices and meet the evolving demands of the profession, the inclusion of key items on the chiropractic equipment list becomes paramount.

Key Points: 
  • This comprehensive article highlights the crucial role of cutting-edge equipment in the success of chiropractic practices.
  • Notably, the article directs practitioners to ChiroEquip.com, a premier online destination offering a diverse array of essential tools from renowned industry brands, including Pivotal Health Solutions and Elite Chiropractic Tables.
  • As practitioners strive to elevate their offices and meet the evolving demands of the profession, the inclusion of key items on the chiropractic equipment list becomes paramount.
  • For chiropractors seeking a comprehensive selection of equipment from renowned industry brands such as Pivotal Health Solutions and Elite Chiropractic Tables, www.ChiroEquip.com emerges as a premier online destination.

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results

Retrieved on: 
Wednesday, January 10, 2024
Distributor, Hope, Woman, Neoplasm, Patient, Endometriosis, Kidney, Neurology, Breast cancer, Malignancy, Freezing, Society, Classification, De novo, Food, Fibroadenoma, Medication, Liver, FDA, CME, Cryoablation, ICE3, Letter, Physician, Human, Lung, Annual general meeting, Kidney cancer, Cryotherapy, Growth, Pharmaceutical industry

Increased Revenues, System, and Probe Sales: Based on our expected preliminary unaudited 2023 results, ProSense® system and disposable probe sales increased by 26% globally over 2022.

Key Points: 
  • Increased Revenues, System, and Probe Sales: Based on our expected preliminary unaudited 2023 results, ProSense® system and disposable probe sales increased by 26% globally over 2022.
  • On a preliminary unaudited basis, as of December 31, 2023, we had cash and cash equivalents, including short-term deposits, of $11 million.
  • The above information reflects preliminary unaudited estimates with respect to certain results of IceCure for the full year ended December 31, 2023, based on currently available information.
  • Because the audit for 2023 is not yet complete, the Company's final results may vary from the preliminary estimates provided herein.

Promaxo Announces System Sales for 2023

Retrieved on: 
Thursday, January 4, 2024
IRE, Robotics, Marketing, FDA, AI, ASC, MRI, Hospital, Cryotherapy, IDN, Medical imaging

OAKLAND, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Promaxo, Inc. (“Promaxo” or the “Company”), a medical imaging, robotics, and AI technology company, today announced sales of 69 systems for the full year ended December 31, 2023.

Key Points: 
  • OAKLAND, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Promaxo, Inc. (“Promaxo” or the “Company”), a medical imaging, robotics, and AI technology company, today announced sales of 69 systems for the full year ended December 31, 2023.
  • System sales were made through the Company’s various sales programs to physician practices, ambulatory surgery centers (ASC), and integrated delivery network (IDN) facilities.
  • “With full year 2023 sales of 69 systems ahead of our target 60 systems and up from 23 systems sold in the year ago period, we capped 2023 on positive momentum, fueling our expectations for strong, steady growth in 2024,” said Dr. Amit Vohra, Founder and CEO of Promaxo.
  • We are executing well on our growth agenda, with strategic investments made in our sales and marketing organization, as well as sales programs, to drive continued market penetration of our portable Promaxo MRI system.”
    Promaxo’s single-sided MRI with AI based imaging system, FDA cleared for in-office use, empowers practices and hospitals to accurately and seamlessly guide prostate interventions under the Promaxo MRI system.